ArticleChinese medical journal2025

Efficacy and safety of upadacitinib through 140 weeks in Chinese adult and adolescent patients with moderate-to-severe atopic dermatitis: Post hoc analysis of the phase 3 Measure Up 1 and AD Up clinical trials.

Li Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.